1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2022, Issue 3
  5. Article
Volume 2022, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Thrombolysis is an established therapeutic modality for patients with high-risk (and some selected intermediate-risk) pulmonary embolism (PE) with hemodynamic instability. Physicians sometimes experience cases where both a high-risk PE and thrombocytopenia coexist. Although thrombocytopenia of <  100 × 103/mm3 is considered a contraindication in patients with ischemic stroke, the safety and outcomes of thrombolysis in patients with acute PE and thrombocytopenia are unknown. This systemic review aimed to pool data on the safety and outcomes of thrombolysis use in patients with PE and platelet count less than 150 × 103/mm3. Patients’ demographics, clinical characteristics, management, type of thrombolytic therapy, and outcomes were extracted and analyzed. Of 283 articles identified through the systematic search, 11 case reports fulfilled the inclusion criteria. The mean age of the patients was 52.27 years, and 54.5% were women. The median platelet level before thrombolysis was 65.50 × 103/mm3. Before thrombolysis was initiated, the lowest and highest platelet levels were 29 × 103/mm3 and 105 × 103/mm3, respectively. Alteplase was used in 10 patients and urokinase in one patient. One patient who had a massive PE died of aspiration pneumonia. Interestingly, no thrombocytopenia-related complications were reported. This systematic review highlights the potential benefits and safety of thrombolysis in patients with acute PE in the context of thrombocytopenia. Nevertheless, data available in the literature concerning this topic are scarce and limited to case reports. More extensive studies on the use of thrombolysis in patients with PE and thrombocytopenia are desperately needed.

Systematic review registration: The protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42021286415.

© 2022 Ata, Ibrahim, Affas, Khan, Younas, Maat, Ali Mohamed, Daoudi, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.33
2022-08-05
2024-11-13
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/3/qmj.2022.33.html?itemId=/content/journals/10.5339/qmj.2022.33&mimeType=html&fmt=ahah

References

  1. Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, et al. Pulmonary embolism. Nat Rev Dis Primers. 2018;:4:18028.
     [Google Scholar]
  2. Brailovsky Y, Allen S, Masic D, Lakhter D, Sethi SS, Darki A. Risk stratification of acute pulmonary embolism. Curr Treat Options Cardiovasc Med. 2021;:23:48.
     [Google Scholar]
  3. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;:41:543–603.
     [Google Scholar]
  4. Rivera-Lebron BN, Rali PM, Tapson VF. The PERT concept: A step-by-step approach to managing pulmonary embolism. Chest. 2021;:159:347–55.
     [Google Scholar]
  5. Hao Q, Dong BR, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2018;12.
     [Google Scholar]
  6. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;:370:1402–11.
     [Google Scholar]
  7. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;:311:2414–21.
     [Google Scholar]
  8. Pillus D, Bruno E, Farcy D, Vilke GM, Childers R. Systematic review: the role of thrombolysis in intermediate-risk pulmonary embolism. J Emerg Med. 2019;:57:517–22.
     [Google Scholar]
  9. Schmidt G, Edinger F, Koch C, Wolff M, Biehl C, Hörbelt R, et al. Ultrasound-accelerated thrombolysis in high-risk perioperative pulmonary embolism: two case reports and review of literature. Perioper Med (Lond). 2021;:10:35.
     [Google Scholar]
  10. Ucar EY. Update on thrombolytic therapy in acute pulmonary thromboembolism. Eurasian J Med. 2019;:51:186–90.
     [Google Scholar]
  11. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, “MOPETT” Investigators. Moderate Pulmonary Embolism Treated With Thrombolysis (from the ’MOPETT’ Trial). Am J Cardiol. 2013;:111:273–7.
     [Google Scholar]
  12. Mowla A, Kamal H, Lail NS, Vaughn C, Shirani P, Mehla S, et al. Intravenous thrombolysis for acute ischemic stroke in patients with thrombocytopenia. J Stroke Cerebrovasc Dis. 2017;:26:1414–8.
     [Google Scholar]
  13. Institute JB. Checklist for case reports. In: Australia. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews [internet]. Available from: https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017_0.pdf..
     [Google Scholar]
  14. Chamsuddin A, Kabbani TA, Nazzal LA, Martin L, Kang B, Lewis C, et al. Abstract No. 65: Catheter thrombolysis in thrombocytopenic cancer patients with deep vein thrombosis. J Vasc Interv Rad. 2008;:19:S26–7:Abstract No. 65:.
     [Google Scholar]
  15. Olbrich K, Wiersbitzky M, Wacke W, Eichler P, Zinke H, Schwock M, et al. Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (lepirudin). Blood Coagul Fibrinolysis. 1998;:9:273–7.
     [Google Scholar]
  16. Seidensticker D, Wilcox J, Gagne P. Treatment of May-Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Cardiovasc Surg. 1998;:6:607–13.
     [Google Scholar]
  17. Weidmann B, Gerber V, Rinas U, Jansen W, Tauchert M. Behandlung einer schweren Lungenembolie bei heparin-induzierter Thrombozytopenie Typ II (HIT II) mit alteplase und lepirudin. Intensivmed Notfallmed. 1999;:36:449–53.
     [Google Scholar]
  18. Burns KEA, McLaren A. Catheter-related right atrial thrombus and pulmonary embolism: A case report and systematic review of the literature. Can Respir J. 2009;:16:163–5.
     [Google Scholar]
  19. Schmidt KI, Fries P, Feldner SK, Schäfers HJ. Successful thrombolysis after pulmonary endarterectomy. Ann Thorac Surg. 2010;:90:2051–3.
     [Google Scholar]
  20. Tsao YT, Wu CC, Hsu YJ, Chu P. Acute right ventricular failure in lupus-associated protein-losing enteropathy. Am J Emerg Med. 2010;:28:845.e1–3.e3.
     [Google Scholar]
  21. Hourmouzis Z, Bhalla MC, Frey JA, Jwayyed S. Pulmonary embolism and heparin-induced thrombocytopenia successfully treated with tissue plasminogen activator and argatroban. Am J Emerg Med. 2015;:33:739.e5–6.
     [Google Scholar]
  22. Vidmar J, Serša I, Kralj E, Popovič P. Unsuccessful percutaneous mechanical thrombectomy in fibrin-rich high-risk pulmonary thromboembolism. Thromb J. 2015;:13:30.
     [Google Scholar]
  23. Zhu T, Pan K, Wang Y. Successful resuscitation with thrombolysis of pulmonary embolism due to thrombotic thrombocytopenic purpura during cardiac arrest. Am J Emerg Med. 2015;:33:132.e3–4.
     [Google Scholar]
  24. Alirezaei T, Hajimoradi B, Pishgahi M, Nekooghadam SM, Golmohamadi M. Successful systemic thrombolytic therapy for massive pulmonary embolism in a patient with breast cancer, brain metastasis, and thrombocytopenia: A case report. Clin Case Rep. 2018;:6:1431–5.
     [Google Scholar]
  25. Badreldin HA, Rimsans J, Connors JM, Wiviott SD. Use of systemic Bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report. Catheter Cardiovasc Interv. 2018;:91:E17-20–e20.
     [Google Scholar]
  26. Villeda GV, Spencer R, Crystal MA, Dayton JD, Krishnan U. Pulmonary artery thromboembolism in a critically ill neonate successfully treated using thrombolytic therapy. Ann Pediatr Cardiol. 2021;:14:215–9.
     [Google Scholar]
  27. Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol. 2015;:94:329–36.
     [Google Scholar]
  28. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;:3:3770–9.
     [Google Scholar]
  29. Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis. 2017;:44:442–7.
     [Google Scholar]
  30. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 2017;:10:15–22.
     [Google Scholar]
  31. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight heparin versus a coumarin for the Prevention of Recurrent venous thromboembolism in Patients with Cancer. N Engl J Med. 2003;:349:146–53.
     [Google Scholar]
  32. Bailly J, Haupt L, Joubert J, Loebenberg P, Jacobson BF, Louw VJ, et al. Heparin-induced thrombocytopenia: an update for the COVID-19 era. S Afr Med J. 2021;:111:841–8.
     [Google Scholar]
  33. Lobbes H, Mainbourg S, Mai V, Douplat M, Provencher S, Lega JC. Risk factors for venous thromboembolism in severe COVID-19: A study-level meta-analysis of 21 studies. Int J Environ Res Public Health. 2021;18.
     [Google Scholar]
  34. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2022;:9:e73–80.
     [Google Scholar]
  35. Tobaiqy M, MacLure K, Elkout H, Stewart D. Thrombotic adverse events reported for moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database. Vaccines. 2021;:9:1326.
     [Google Scholar]
  36. Hernández-Huerta MT, Pérez-Santiago AD, Pérez-Campos Mayoral L, Sánchez Navarro LM, Rodal Canales FJ, Majluf-Cruz A, et al. Mechanisms of immunothrombosis by SARS-CoV-2. Biomolecules. 2021;11.
     [Google Scholar]
/content/journals/10.5339/qmj.2022.33
Loading
Safety and outcomes of thrombolytic therapy in patients with pulmonary embolism and thrombocytopenia: A systematic review
Qatar Medical Journal 2022, 33 (2022); https://doi.org/10.5339/qmj.2022.33
/content/journals/10.5339/qmj.2022.33
/content/journals/10.5339/qmj.2022.33
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): anticoagulation, PE, platelets, Pulmonary embolism, Thrombocytopenia and thrombolysis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error